Results 11 to 20 of about 6,652 (162)
Conversion from cilostazol to OPC‐13015 linked to mitigation of cognitive impairment
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2021 Introduction Cilostazol may be a novel therapeutic agent for Alzheimer's disease. Its metabolite, OPC‐13015, has a stronger inhibitory effect on type 3 phosphodiesterase than cilostazol.
Satoshi Saito +8 more
doaj +1 more source
Effect of cilostazol on arteriovenous fistula in hemodialysis patients
Nefrología (English Edition), 2021 Background: The maturation and patency of permanent vascular access are critical in patients requiring hemodialysis. Although numerus trials have been attempted to achieve permanently patent vascular access, little have been noticeable.
Jae Wan Jeon +8 more
doaj +3 more sources
Cilostazol Suppresses IL-23 Production in Human Dendritic Cells via an AMPK-Dependent Pathway
Cellular Physiology and Biochemistry, 2016 Background/Aims: Cilostazol has been previously demonstrated to inhibit IL-23 production in human synovial macrophages via a RhoA/ROCK-dependent pathway.
Quanxing Shi +9 more
doaj +1 more source
Cilostazol prevents endothelin-induced smooth muscle constriction and proliferation. [PDF]
PLoS ONE, 2012 Cilostazol is a phosphodiesterase inhibitor that has been shown to inhibit platelet activation. Endothelin is known to be the most potent endogenous growth promoting and vasoactive peptide.
Yoshifumi Kawanabe +6 more
doaj +1 more source
Cilostazol Upregulates Autophagy via SIRT1 Activation: Reducing Amyloid-β Peptide and APP-CTFβ Levels in Neuronal Cells. [PDF]
PLoS ONE, 2015 Autophagy is a vital pathway for the removal of β-amyloid peptide (Aβ) and the aggregated proteins that cause Alzheimer's disease (AD). We previously found that cilostazol induced SIRT1 expression and its activity in neuronal cells, and thus, we ...
Hye Rin Lee +8 more
doaj +1 more source
Cilostazol-induced acute tubulointerstitial nephritis accompanied by IgA nephropathy: a case report
BMC Nephrology, 2018 Background Cilostazol is an antiplatelet drug that is widely prescribed for the prevention of secondary stroke. Adverse reactions to cilostazol include headaches, palpitations, and diarrhea. Little is known about the nephrotoxicity of cilostazol, such as
Hisato Shima +7 more
doaj +1 more source
PLoS ONE, 2015 BackgroundCilostazol, a selective phosphodiesterase 3 (PDE3) inhibitor, is known as an anti-platelet drug and acts directly on platelets. Cilostazol has been shown to exhibit vascular protection in ischemic diseases. Although vascular endothelium-derived
Ayako Hashimoto +4 more
doaj +1 more source
Clinics, 2012 OBJECTIVES: The clinical significance of ischemia/reperfusion of the lower extremities demands further investigation to enable the development of more effective therapeutic alternatives.
Mariana R.G.A. Santos +5 more
doaj +1 more source
Cilostazol: an antiplatelet agent for the neurointerventionist?
Journal of NeuroInterventional Surgery, 2014 Antiplatelet agents are essential for the successful management of patients undergoing a variety of neurointerventional procedures. The most commonly used anti-platelet agents are aspirin, clopidogrel and prasugrel. However, there exist an alternative class of anti-platelet agent that may prove useful for neurointerventionists.
Bhogal, P. +2 more
openaire +3 more sources
5. THE EFFECT OF CILOSTAZOL TO ARTERIAL STIFFNESS IN THE HYPERTENSIVE PATIENT
Artery Research, 2009 Background: Cilostazol is a potent antiplatelet agent that selectively inhibits phosphodiesterase III, and also it has beneficial effect to peripheral arterial disease, like intermittent claudication, by direct vasodilative action.
Jin Oh Na +8 more
doaj +1 more source